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Abstract 
Background: Gliomas are the most common primary tumors in the central nervous system. Due to complicated 
signaling pathways involved in glioma progression, effective targets for treatment and biomarkers for prognosis pre-
diction are still scant.
Results: In this study we revealed that a new microRNA (miR), the miR-221, was highly expressed in the glioma 
cells, and suppression of miR-221 resulted in decreased cellular proliferation, migration, and invasion in glioma cells. 
Mechanistic experiments validated that miR-221 participates in regulating glioma cells proliferation and invasion via 
suppression of a direct target gene, the Semaphorin 3B (SEMA3B). The rescue experiment with miR-221 and SEMA3B 
both knockdown results in significant reversion of miR-221 induced phenotypes.
Conclusion: Taken together, our findings highlight an unappreciated role for miR-221 and SEMA3B in glioma.
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Background
Glioma is one of the major human primary brain tumors 
[1], which is characterized by tumor cell local invasion 
and migration from remote distances [2]. Though sig-
nificant progress has been made in surgical and chemo-
therapy treatment, the prognosis of patients with glioma 
remains poor [3]. Therefore, new therapeutic strategies 
for the management of glioma is therefore essential.
MicroRNAs (miRNAs) are endogenous small non-
coding RNAs of about 22 nucleotides in length, which 
regulate gene expression post-transcriptionally. MiR-
NAs recognize and repress target mRNAs based on 
sequence complementarity between the miRNA and the 
target mRNA, and are critical in regulating a variety of 
biological processes, including cell cycle, differentiation, 
development, and metabolism, as well as diseases such as 
diabetes, neurodegenerative disorders, and cancers [4]. 
Emerging literatures have found that aberrant miRNAs 
could act as oncogenes or tumor suppressors in glioma 
tumorigenesis [5]. Dysregulation of these miRNAs con-
tributes to tumorigenesis by stimulating glioma cells pro-
liferation, angiogenesis and invasion [6, 7]. Among these 
miRNAs the miR-221/222 are attractive to researchers 
because of their bimodal function in the tumorigenesis of 
human cancers [8]. They are encoded in tandem from a 
gene cluster located on chromosome X, and both tumor-
suppressive and oncogenic roles of miR-221/222 have 
been reported in a series of cancer types [9]. A couple of 
up-to-date studies have revealed collaborations between 
the expression of miR-221/222 and glioma carcinogen-
esis, since higher miR-221/222 expression correlated 
with poorer prognostic status of patients, which might be 
attributed to their attenuated sensitivity to chemother-
apy and radiotherapy [10]; in addition Zhang et  al. [11] 
reported plasma miR-221/222 family levels were signifi-
cantly upregulated in glioma patients, and high positive 
plasma miR-221 and miR-222 were both correlated with 
poor survival rate. These studies suggested that detection 
of the miRNA-221/222 family should be considered as a 
new additional tool to better characterize glioma diag-
nostic and predictive value of miR-221/222 family for 
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glioma. However, functions of miR-221/222 in glioma 
tumorigenesis and development are poorly understood.
In this study, we aimed at miR-221 as a candidate 
miRNA according to the RT-qPCR screening and vali-
dated its expression in glioma tissues and cell lines. Fur-
ther researches to assess the effects of miR-221 on glioma 
cells proliferation and invasion were carried on, as well 
as the regulating mechanism on SEMA3B gene was 
explored.
Results
miR‑221 expression was elevated in glioma cells
We aimed to explore the potential functions and molecu-
lar mechanisms of miR-221/222 family in glioma. The 
U87MG, U251, A172, T98G and LN-18 glioma cell lines 
and the normal human astrocytes cell line NHA were 
chosen for further research. The expression of miR-
221 and miR-222 were determined by qPCR, the result 
showed that miR-221 was greatly upregulated in glioma 
cells, while miR-222 was only slightly upregulated (Fig-
ure 1a). Furthermore, a total of 30 cases of human glioma 
samples were chosen to detect the miR-221/222 expres-
sion levels in glioma tissues compared with the paracan-
cerous tissue, respectively. Interestingly, our data showed 
that the only expression of miR-221 between the glioma 
group and the paraglioma group showed significant 
increasing, but miR-222 expression had no obvious dif-
ference (Figure 1b).
Suppression of miR‑221 inhibits cell growth in glioma cells
To examine the function of miR-221, we firstly 
silenced the expression of miR-221 using the miR-221 
inhibitor in glioma cells. After the U87MG and U251 
cells were treated with 100 pM of miR-221 for 48 h, we 
employed the qPCR to detect the expression level of 
miR-221, and the result showed that miR-221 was sig-
nificantly reduced both in U87MG and in U251 cells 
(Figure 2a). Then we used these glioma cells with miR-
221 knockdown to test whether miR-221 participates 
in the cell growth of glioma cells. After treated with 
miR-221 inhibitor (100 pM) in U87MG and U251 cells 
for 48 h, we replated these cells in a 96-well plate and 
the CCK-8 assay was performed to verify the glioma 
cell proliferation up to 3 days. Our results showed that 
the proliferation rate was gradually decreased in cells 
transfected with miR-221 inhibitor compared with the 
media control and the scramble control; significant 
difference was observed at 72  h time point in both 
U87MG cells and U251 cells (Figure 2b, c). These data 
indicated that miR-221 participated in the prolifera-
tion of glioma cells and suppression of miR-221 could 
inhibit cell growth.
Suppression of miR‑221 inhibits glioma cells migration 
and invasion
Glioma cells exerts powerful migration and invasion, and 
plenty of genes and micro RNAs have been revealed in 
contribution to the metastasis. We hypothesized that 
high expression level of miR-221 in glioma cells might 
be involved in this pathologic process in glioma cells. To 
study whether miR-221 indeed participates in the inva-
sion, we performed transwell assay without matrigel 
to detect the migration ability and transwell assay with 
matrigel to verify the invasion ability. As shown in the 
Figure  3, compared with the media control and the 
scramble control, the miR-221 inhibitor treated U87MG 
and U251 cells showed significant lower rates both in 
migration ability (Figure 3a, b) and invasion ability (Fig-
ure  3c, d), both were clearly shown in the photography 
and quantitative analysis.
Figure 1 miR-221 expression in human glioma cells and glioma tissues from patients. a RT-qPCR showed the measurement of miR-221 and miR-
222 expressions in different human glioma cell lines. b RT-qPCR assay showed the measurement of miR-221 and miR-222 expressions in 30 glioma 
tissues or paracarcinoma tissues from patients. GAPDH serves as the endogenous control. *p < 0.05; **p < 0.01.
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SEMA3B is the target for miR‑221
To elucidate the detailed mechanisms of miR-221 in regu-
lating glioma cell biology, we predicted its potential tar-
gets using TargetScan (http://www.targetscan.org). We 
found that the Semaphorin 3B gene (SEMA3B) is a theo-
retical target of miR-221, and there are seven miR-221 
conserved binding sites on the 3′ UTR region of SEMA3B 
mRNA (Figure  4a). Most importantly, SEMA3B regulates 
neuronal migration and acts as a tumor a suppressor gene 
[12]. We firstly analyzed the correlation of the expression of 
miR-221 and SEMA3B level in 30 human glioma samples 
using RT-qPCR, and out result presented that there was a 
negative correlation between miR-221 and SEMA3B (Fig-
ure 4b). We manipulated the expression of miR-221 using 
mimic or inhibitor both in the Normal Human Astrocytes 
(NHA) and human glioma U87MG cells, and the SEMA3B 
Figure 2 Suppression of miR-221 inhibits cell growth in U87MG and U251 glioma cells. a RT-qPCR was performed to measure miR-221 expression 
levels in loss of function model. Scr scramble, Inh miR-221 inhibitor. CCK-8 assay was employed to detect the cell proliferation in U87MG cells (b) 
and U251 cells (c). Glioma cells were treated with 100 pM of miR-221 inhibitors for 48 h and then cells were replaced into a 96-well plate for up to 
72 h, and cells were collected for assigned time points for CCK-8 assay *p < 0.05; **p < 0.01.
Figure 3 Suppression of miR-221 inhibits migration and invasion in glioma cells. a Photography and b quantitative assay of the transwell assay 
without matrigel coated was employed to detect the cell migration ability in U87MG and U251 cells with miR-221 knockdown using miR-221 
inhibitor. c Photography and d quantitative assay of the transwell assay with matrigel coated was employed to detect the cell invasion ability in 
U87MG and U251 cells with miR-221 knockdown. *p < 0.05; **p < 0.01.
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level was detected using western blot. We found that 
although miR-221 inhibitor could upregulate the protein 
level of SEMA3B, and miR-221 mimic could downregulate 
expression of SEMA3B both in the NHA cells and in the 
U87MG cells, respectively, the regulating degree was much 
more significant in the U87MG cells (Figure 4c). In addi-
tion, we used luciferase assay reporters containing the wild 
type 3′UTR sequence and the mutant type (with 3 of the 
miR-221 binding sites changed) of SEMA3B mRNA to test 
the effect of miR-221 on the transcriptional activity. Rela-
tive luciferase activity upon transfection of scramble con-
trol (Scr) or different dosage of miR-221 mimic (50 and 
100 pM) demonstrated that only the miR-152 mimic, but 
not the scramble, suppressed transcriptional activity of the 
3′UTR of SEMA3B in a dose dependent manner (Figure 4d, 
left panel). On the other hand, in the mutant vector, inhibi-
tory effect of miR-221 mimic on the 3′UTR of SEMA3B 
mRNA was not observed (Figure 4d, right panel).
Knockdown endogenous SEMA3B reversed the effect 
of miR‑221 Inhibitor
In order to confirm whether miR-221 indeed exerts its 
function through its target SEMA3B, we established a 
U87MG cell line in which the SEMA3B gene was stably 
silenced (SEMA3B KD) by SEMA3B shRNA (Figure 5a). 
miR-221 inhibitor and scramble control were trans-
fected into the wild type U87MG cells and the SEMA3B 
KD U87MG cells, and CCK-8 assay and transwell assay 
were employed respectively to test the cell proliferation, 
migration, and invasion ability changes. The results dem-
onstrated that the miR-221 inhibitor could only suppress 
the cell proliferation in the wild type U87MG cells but 
not in the SEMA3B cell (Figure 5b). Inhibitory effect of 
miR-221 on U87MG cell invasion and invasion were only 
observed in the wild type U87MG cells as expected (Fig-
ure 5c, d). These data suggest that miR-221 mediated cell 
growth and invasion through its transcriptional modula-
tion on SEMA3B.
Discussion
Glioma is the most general primary tumor in nervous 
system with the highest mortality and mortality among 
endocranial tumors for its forceful malignant prolifera-
tion and invasion [13, 14]. An early diagnosis of glioma 
in patients greatly increases the chances for successful 
treatment, therefore a specific and sensitive marker is 
very important. Previous studies for identifying glioma 
biomarkers of glioma had mainly focused on proteins 
Figure 4 SEMA3B is a target of miR-221. a Binding sites of miR-221 (the black letters) on the SEMA3B mRNA 3′UTR. b An inverse correlation 
between miR-221 and SEMA3B was observed by Spearman correlation analysis in 30 cased of human glioma tissues. c Western blot was performed 
to detect the protein level of SEMA3B in NHA and U87MG cells with miR-221 overexpression or knockdown using miR-221 inhibitor or mimic 
(100 pM) for 48 h, respectively. d Luciferase reporter plasmids and miR-221 mimics were co-transfected to cells, and then the luciferase reporter 
assay was employed to detect luciferase activity. *p < 0.05; **p < 0.01.
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[15], however, miRNAs have absorbed more and more 
of attention from researchers for the advantage of easy 
and low cost of determination as new molecular mark-
ers [16]. The aim of this study is to evaluate the function 
of miR-221 in human glioma and the potential as diag-
nostic and treatment marker. In the current study, we 
have found that miR-221 level in glioma is significantly 
higher than that in non-glioma tissues or cells; that miR-
221 participates in glioma cell proliferation, migration 
and invasion; that miR-221 plays its biological roles via 
negatively regulating the SEMA3B gene in glioma. All the 
results suggested that miR-221 could be used as potential 
biomarkers in glioma identification, early diagnosis, and 
developing new therapeutic strategies.
Semaphorins families are a large number of cytoplas-
mic and membrane-bound proteins, including SEMA1–
A4, B1–B3, and C1 in vertebrate [17]. The SEMA3B gene 
is widely expressed in the mammary gland, colon, lung, 
kidney, and so on [18]. The SEMA3B protein is an antag-
onist of receptors for neuropilins 1 and 2 (Np1 and Np2) 
that also act as receptors for several isoforms of vascu-
lar endothelial growth factor (VEGF), which is a general 
initiator of tumor angiogenesis, and thus SEMA3B sup-
presses vascular growth in tumors [19]. Suppression in 
transcriptional activity of this gene in tumors indicate 
that SEMA3B may participate in cell growth suppres-
sion in the kidney, ovary, and colon cancers [20]. In our 
study, the expression level of SEMA3B in glioma cells 
was found lower than normal glia cells, which is the first 
observation of SEMA3B in glioma cells to our knowledge 
and further result suggest that SEMA3B participates in 
the regulation of glioma cells proliferation and invasion. 
Though SEMA3B was verified for the target of miR-221 
by us for the first time, there were still some other tar-
gets of miR-221 existence, which needed us to explore in 
future.
Mounting evidence implicates miRNAs as regulators 
of the tumor phenotype through their ability to modulate 
the expression of critical genes and signaling networks 
involved in tumorigenesis and downstream malignant 
processes [21]. miR-221/222 act as oncogenic miRNAs 
that facilitate cell proliferation via down-regulation of 
p27Kip1 and/or p57Kip2, which negatively regulate cell 
cycle progression from G1- to S-phase [22–24]. Although 
various studies present the mechanism by which miR-
221 functions in cancer cells, the oncogene or tumor 
suppression capability of miR-221 in glioma was poorly 
understood since there were only few papers before this 
Figure 5 Knockdown endogenous SEMA3B reversed the effect of miR-221 Inhibitor. a Western blot showed SEMA3B level in a U87MG cells with 
SEMA3B gene stably silenced, b CCK-8 assay was employed to detect the cell proliferation in U87MG wild type and SEMA3B KD cells treated with 
scramble or miR-221 inhibitor (100 pM). Transwell assay without matrigel coated for testing cell migration (c) and transwell assay with matrigel 
coated was employed to detect the cell invasion ability (d) in U87MG cells treated with scramble or miR-221 inhibitor (100 pM). *p < 0.05; 
**p < 0.01.
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study. Zhang et al. [25] demonstrated that high levels of 
miR-221/222 expression in gliomas confer highly aggres-
sive invasion and poorer overall survival through by tar-
geting TIMP3 and act as prognostic factors for glioma 
patients; Cristina et  al. reported that overexpression 
of miR-221/222 produces an increase in sensitivity to 
temozolomide via a reduction in the level of MGMT. In 
addition, these miRNAs increase DNA damage, confer-
ring oncogenic features to glioma cells [26]. In this study, 
we found miR-221, but not miR-222 level is significantly 
high in the glioma tissues and cells, and manipulating of 
expression of miR-221 could result in glioma cell prolif-
eration, migration and invasion ability change, indicating 
that miR-221 is a critical oncogene in glioma. However, 
exploring the detailed function of miR-221/222 and 
searching more targets of miR-221/222 in glioma cells are 
the problems to be solved.
Conclusions
In summary, we described that miR-221 expression level 
is associated with glioma tumorigenesis. The loss of func-
tion of miR-221 in glioma cell line suggests that knock-
down of miR-221 inhibits cell proliferation and invasion. 
Mechanistically, SEMA3B is the direct target of miR-221, 
which acts as the tumor suppressor in glioma. These 
results suggest that miR-221 plays an important role in 
glioma tumorigenesis and could be served as a potential 




There were totally 102 patients involved at the initia-
tion of this study in the Department of neurology, Bei-
jing Friendship Hospital, Capital Medical University, and 
only 30 cases with surgical resection of brain glioma were 
collected according to the strict inclusive criteria: (1) 
no other types of tumor, viral hepatitis, or autoimmune 
diseases; (2) no preoperative chemotherapy or radiation 
therapy. The paracancerous tissue was defined as 2  cm 
away from lesions. All specimens were obtained under 
sterile conditions during surgery. All patients were given 
informed consent, and this study was approved by the 
Ethic Committee Board of Capital Medical University.
Cell preparation and culture
NHA cells were purchased from Lonza Company (CA, 
USA), U87MG, U251, A172, T98G and LN-18 glioma 
cell lines were purchased from ATCC Company (VA, 
USA). All the cells were maintained in DMEM medium 
with high glucose and sodium pyruvate, supplemented 
with 10% fetal bovine serum and antibiotics (100 units/
ml penicillin and 100  mg/ml streptomycin). Cells were 
incubated at 37°C in a humidified atmosphere of 5% CO2 
in air.
Transfection of shRNA
The shRNA directed against Sema3b and the control 
shRNA were both chemically synthesized, the sequence of 
shRNA used for Sema3b were Sense: 5′-GGCCGACUG 
UACUAAAGUAUU-3′, Antisense: 5′-UACUUUAGUAC 
AGUCGGCCUU-3′; the sequence of control shRNA 
were Sense: 5′-GAUAGACAAAUGACGAAUGCGUA 
UU-3′, Antisense: 5′-TCGCTTCGTCTTTGTCTTCU 
U-3′. When the cells reached 70% confluent, Oligo-
fectamine reagent from Invitrogen (Life Technology, NY, 
USA) was employed to perform the in  vitro transfec-
tion according to the manufacturer’s instructions, and 
cells were harvested 48  h after transfection for further 
experiments.
CCK‑8 assay
Cells were seeded in 96-well plates at confluence of 2,000 
cells per well. The absorptions of the cells were measured 
using CCK-8 kit (Dojindo Laboratories, Japan) based on 
the manufacturer’s instruction at indicated time points.
Transwell assay
Transwell membranes were coated with matrigel for 6  h 
for invasion assay, or without matrigel for migration assay. 
5  ×  104 cells were seeded onto the upper chamber, and 
800 μl medium with 10% fetal bovine serum was added to 
the lower chamber. After incubation for 24 h, cells adher-
ing to the upper surface of the membrane were removed 
with a cotton swab. The invasion or migration cells, which 
adhered to the lower surface, were fixed with 4% paraform-
aldehyde and stained with 0.1% crystal violet. The cells 
were finally extracted with 33% acetic acid and detected 
quantitatively using microplate reader (at 570  nm). Data 
were obtained from three independent experiments.
Quantitative real‑time PCR (qPCR)
RNAs were isolated using an RNAvzol reagent (Vigorous 
Biotechnology, Beijing, China) according to the manu-
facturer’s protocol. cDNA was synthesized with M-MLV 
reverse transcriptase (Promega, WI, USA) in a 20  μl 
reaction mixture (2  µg total RNA, 2  µl 10  ×  RT buffer, 
1 µl M-MLV enzyme, 1 µl dNTP, 1 µl miR primer, 1 µl ran-
dom primer, and ddH2O to 20 µl) at 37°C for 2 h. RT-qPCR 
was performed in the ABI 7500 real-time RT-PCR sys-
tem with reagents from the SYBR® Green Real-time PCR 
Master Mix (TOYOBO, Japan) and the appropriate prim-
ers in a 20 µl reaction system (10 µl Master mixture, 1 µl 
cDNA, 1 µl forward primer and 1 µl reverse primer, and 
7 µl ddH2O). A 10 min “hot start” was carried on firstly, 
and then 40 cycles were run with each cycle including a 
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denaturation step at 95°C for 10  s, annealing starting at 
60°C for 20 s, and amplification at 72°C for 30 s. For quan-
tification of the target gene, the ΔΔCt algorithm was used. 
The primers for miR-221, miR-222 and U6 were all pur-
chased from RiboBio Company. All experiments were per-
formed at least three times and the mean values were used.
Western blot analysis
Cells were washed twice in ice-cold PBS and lysed in 
1  ×  lysis buffer (Cell Signal Technology, CA, USA), the 
protein concentration of each sample was detected using 
BCA assay before loading, and then whole cell extracts 
(50 μg protein) was analyzed by 12% SDS PAGE and sub-
sequently transferred onto nitrocellulose membranes. For 
immunoblot experiments, membranes were blocked for 
1 h with 5% skimmed milk powder in TBS containing 0.1% 
Tween-20, and incubated with primary antibody at 4°C 
overnight. The rabbit polyclonal anti-SEMA3B antibody 
(code: sc-21204-R, 1:500 dilution) and the goat polyclonal 
anti-GAPDH antibody (code: sc-48167, 1:2,000 dilution) 
were both purchased from Santa Cruz Biotechnologies 
(CA, USA). The secondary antibodies were all purchased 
from Zhongshanjinqiao Company (Beijing, China), bound 
antibodies were visualized with an enhanced chemilumi-
nescence system (DuPont, Boston, MA). The densitomet-
ric analysis was been carried on using the ImageJ software 
(Fiji Software), and the percentage of inhibition was nor-
malized as SEMA3B/GAPDH.
Luciferase reporter assay
The luciferase reporter containing the 3′ UTR of the 
human SEMA3B gene was purchased from RiboBio 
Company (Guangzhou, China). HeLa cells were co-trans-
fected with miR-221 mimics (100  pM) with luciferase 
reporter for 48 h, and Renilla luciferase expression con-
struct. Cells were harvested 36  h post-transfection and 
assayed with Dual Luciferase Assay (Promega, WI, USA) 
according to the manufacturer’s instructions. Luciferase 
activity was measured and normalized to Renilla lucif-
erase activity. Three independent experiments were per-
formed in triplicate.
Statistical analysis
The data are expressed as mean  ±  standard deviation 
(SD). Comparisons between groups were analyzed using 
Student’s t test or ANOVA. Differences were considered 
to be statistically significant at p < 0.05.
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